S&P Futures
3,828.00 -6.00 (-0.16%) Dow Futures
30,882.00 -54.00 (-0.17%) Nasdaq Futures
11,797.75 -10.75 (-0.09%) Russell 2000 Futures
1,736.90 -4.80 (-0.28%) Crude Oil
100.27 +0.77 (+0.77%) Gold
1,769.70 +5.80 (+0.33%)
NanoViricides, Inc. (NNVC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.8800 |
| Open | 2.0600 |
| Bid | 1.5200 x 800 |
| Ask | 2.2500 x 3000 |
| Day's Range | 1.8000 - 2.0600 |
| 52 Week Range | 1.0400 - 7.8600 |
| Volume | |
| Avg. Volume | 69,393 |
| Market Cap | 21.782M |
| Beta (5Y Monthly) | 0.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8180 |
| Earnings Date | Nov 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.50 |
- ACCESSWIRE
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application
SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed the quarterly report for third quarter of its 2022 fiscal year with the Securities and Exchange Commission.
- Benzinga
NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis
NanoViricides Inc (NYSE: NNVC) has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be strongly associated with the occurrence of severe hepatitis syndrome in some children. The company says its top priority remains to initiate human trials of its SARS-CoV-2 drug candidate NV-CoV-2 to combat COVID-19. NanoViricides expects filing a clinical trial application for COVID-19 to occur relatively soon, althoug
- ACCESSWIRE
NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis
SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform reports that it has begun drug development to combat recent cases of severe pediatric hepatitis.
